Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Bovine Heparin Compared to Porcine Heparin to Demonstrate Bioequivalence

Marco Khiella, Walter Jeske, PhD, Jeanine Walenga, PhD, Omer Iqbal, MD, Rajan Laddu, Fakiha Siddiqui, Mamdouh Bakhos, MD

Blood (2018) 132 (Supplement 1): 1253.

https://doi.org/10.1182/blood-2018-99-118809

Published: 2018

Journal Articles

Comparative Studies on a Branded Recombinant Factor VIIa and Its Generic Version to Demonstrate Bioequivalence

Nasir Sadeghi, Zafar Siddiqui, Omer Iqbal, Schuharazad Abro, Debra Hoppensteadt, PhD, Michael Mosier, Jeanine Walenga, Jawed Fareed, PhD, Ahmed Kouta

Blood (2017) 130 (Supplement 1): 4868.

https://doi.org/10.1182/blood.V130.Suppl_1.4868.4868

Published: 2017

Journal Articles

Phase 1, Open-Label, Randomized, Bioequivalence Study of 2 Bendamustine Hydrochloride Formulations; A Ready-to-Dilute Low-Volume, Rapid Infusion Solution and a Lyophilized Powder Formulation

W Jeffrey Edenfield, MD, Bassam Mattar, MD, Stephen P Anthony, DO, Peter Mutch, Brian Chanas, Mark Smith

Blood (2015) 126 (23): 4857.

https://doi.org/10.1182/blood.V126.23.4857.4857

Published: 2015

Journal Articles

Relative Oral Bioequivalence of Two 6-Mercaptopurine (6-MP) Liquid Formulations in Children with Acute Lymphoblastic Leukemia (ALL)

Jaszianne A. Tolbert, MD, Keith J. August, MD MS, Susan M Abdel-Rahman, PharmD, Scott J Weir, PharmD, PhD, J Steven Leeder, PharmD, PhD, Kathleen A Neville, MD MS

Blood (2014) 124 (21): 2242.

https://doi.org/10.1182/blood.V124.21.2242.2242

Published: 2014

Journal Articles

Towards Phase 2/3 Trials for Epstein - Barr Virus (EBV)-Associated Malignancies,

Jun Ando, MD, PhD, Minhtran Charlotte Ngo, Sravya Ennamuri, Jiali Sun, PhD, Helen E. Heslop, MD, Catherine M. Bollard, MD, Carl H. June, MD, Ann M. Leen, PhD, Stephen Gottschalk, MD, Cliona M. Rooney, PhD

Blood (2011) 118 (21): 4043.

https://doi.org/10.1182/blood.V118.21.4043.4043

Published: 2011

Journal Articles

BIOEQUIVALENCE of a BIOSIMILAR FILGRASTIM and REFERENCE FILGRASTIM: IMPACT ON the MOBILIZATION of CD34+ PERIPHERAL BLOOD PROGENITOR CELLS in a RANDOMIZED, PHASE I STUDY.

Miguel H Bronchud, Cornelius F Waller, Stuart J Mair, Rodeina Challand

Blood (2009) 114 (22): 4564.

https://doi.org/10.1182/blood.V114.22.4564.4564

Published: 2009

Journal Articles

Bioequivalence, Heat Stability and Reconstitution of Room Temperature Stable Recombinant Activated Factor VII (rFVIIa-RT)

Prasad Mathew, MD, Jens Bjerre, MD, David L. Cooper, MD, MBA

Blood (2008) 112 (11): 4083.

https://doi.org/10.1182/blood.V112.11.4083.4083

Published: 2008

NARROW

Bovine Heparin Compared to Porcine Heparin to Demonstrate Bioequivalence

Comparative Studies on a Branded Recombinant Factor VIIa and Its Generic Version to Demonstrate Bioequivalence

Phase 1, Open-Label, Randomized, Bioequivalence Study of 2 Bendamustine Hydrochloride Formulations; A Ready-to-Dilute Low-Volume, Rapid Infusion Solution and a Lyophilized Powder Formulation

Relative Oral Bioequivalence of Two 6-Mercaptopurine (6-MP) Liquid Formulations in Children with Acute Lymphoblastic Leukemia (ALL)

Towards Phase 2/3 Trials for Epstein - Barr Virus (EBV)-Associated Malignancies,

BIOEQUIVALENCE of a BIOSIMILAR FILGRASTIM and REFERENCE FILGRASTIM: IMPACT ON the MOBILIZATION of CD34+ PERIPHERAL BLOOD PROGENITOR CELLS in a RANDOMIZED, PHASE I STUDY.

Bioequivalence, Heat Stability and Reconstitution of Room Temperature Stable Recombinant Activated Factor VII (rFVIIa-RT)

Email alerts

ASH Publications

American Society of Hematology

Bovine Heparin Compared to Porcine Heparin to Demonstrate Bioequivalence

Comparative Studies on a Branded Recombinant Factor VIIa and Its Generic Version to Demonstrate Bioequivalence

Phase 1, Open-Label, Randomized, Bioequivalence Study of 2 Bendamustine Hydrochloride Formulations; A Ready-to-Dilute Low-Volume, Rapid Infusion Solution and a Lyophilized Powder Formulation

Relative Oral Bioequivalence of Two 6-Mercaptopurine (6-MP) Liquid Formulations in Children with Acute Lymphoblastic Leukemia (ALL)

Towards Phase 2/3 Trials for Epstein - Barr Virus (EBV)-Associated Malignancies,

BIOEQUIVALENCE of a BIOSIMILAR FILGRASTIM and REFERENCE FILGRASTIM: IMPACT ON the MOBILIZATION of CD34+ PERIPHERAL BLOOD PROGENITOR CELLS in a RANDOMIZED, PHASE I STUDY.

Bioequivalence, Heat Stability and Reconstitution of Room Temperature Stable Recombinant Activated Factor VII (rFVIIa-RT)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only